1 Introduction to Research & Analysis Reports
1.1 Metachromatic Leukodystrophy Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Metachromatic Leukodystrophy Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Metachromatic Leukodystrophy Treatment Overall Market Size
2.1 Global Metachromatic Leukodystrophy Treatment Market Size: 2022 VS 2029
2.2 Global Metachromatic Leukodystrophy Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Metachromatic Leukodystrophy Treatment Players in Global Market
3.2 Top Global Metachromatic Leukodystrophy Treatment Companies Ranked by Revenue
3.3 Global Metachromatic Leukodystrophy Treatment Revenue by Companies
3.4 Top 3 and Top 5 Metachromatic Leukodystrophy Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Metachromatic Leukodystrophy Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Metachromatic Leukodystrophy Treatment Players in Global Market
3.6.1 List of Global Tier 1 Metachromatic Leukodystrophy Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Metachromatic Leukodystrophy Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Metachromatic Leukodystrophy Treatment Market Size Markets, 2022 & 2029
4.1.2 Tablet
4.1.3 Capsule
4.1.4 Others
4.2 By Type – Global Metachromatic Leukodystrophy Treatment Revenue & Forecasts
4.2.1 By Type – Global Metachromatic Leukodystrophy Treatment Revenue, 2018-2023
4.2.2 By Type – Global Metachromatic Leukodystrophy Treatment Revenue, 2024-2029
4.2.3 By Type – Global Metachromatic Leukodystrophy Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Metachromatic Leukodystrophy Treatment Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Laboratory
5.1.5 Others
5.2 By Application – Global Metachromatic Leukodystrophy Treatment Revenue & Forecasts
5.2.1 By Application – Global Metachromatic Leukodystrophy Treatment Revenue, 2018-2023
5.2.2 By Application – Global Metachromatic Leukodystrophy Treatment Revenue, 2024-2029
5.2.3 By Application – Global Metachromatic Leukodystrophy Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Metachromatic Leukodystrophy Treatment Market Size, 2022 & 2029
6.2 By Region – Global Metachromatic Leukodystrophy Treatment Revenue & Forecasts
6.2.1 By Region – Global Metachromatic Leukodystrophy Treatment Revenue, 2018-2023
6.2.2 By Region – Global Metachromatic Leukodystrophy Treatment Revenue, 2024-2029
6.2.3 By Region – Global Metachromatic Leukodystrophy Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Metachromatic Leukodystrophy Treatment Revenue, 2018-2029
6.3.2 US Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.3.3 Canada Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.3.4 Mexico Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Metachromatic Leukodystrophy Treatment Revenue, 2018-2029
6.4.2 Germany Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.4.3 France Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.4.4 U.K. Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.4.5 Italy Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.4.6 Russia Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.4.8 Benelux Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Metachromatic Leukodystrophy Treatment Revenue, 2018-2029
6.5.2 China Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.5.3 Japan Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.5.4 South Korea Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.5.6 India Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Metachromatic Leukodystrophy Treatment Revenue, 2018-2029
6.6.2 Brazil Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.6.3 Argentina Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Metachromatic Leukodystrophy Treatment Revenue, 2018-2029
6.7.2 Turkey Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.7.3 Israel Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
6.7.5 UAE Metachromatic Leukodystrophy Treatment Market Size, 2018-2029
7 Metachromatic Leukodystrophy Treatment Companies Profiles
7.1 ArmaGen, Inc.
7.1.1 ArmaGen, Inc. Company Summary
7.1.2 ArmaGen, Inc. Business Overview
7.1.3 ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Major Product Offerings
7.1.4 ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.1.5 ArmaGen, Inc. Key News & Latest Developments
7.2 GlaxoSmithKline Plc
7.2.1 GlaxoSmithKline Plc Company Summary
7.2.2 GlaxoSmithKline Plc Business Overview
7.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Major Product Offerings
7.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.2.5 GlaxoSmithKline Plc Key News & Latest Developments
7.3 Recursion Pharmaceuticals, Inc.
7.3.1 Recursion Pharmaceuticals, Inc. Company Summary
7.3.2 Recursion Pharmaceuticals, Inc. Business Overview
7.3.3 Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Major Product Offerings
7.3.4 Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.3.5 Recursion Pharmaceuticals, Inc. Key News & Latest Developments
7.4 RegenxBio, Inc.
7.4.1 RegenxBio, Inc. Company Summary
7.4.2 RegenxBio, Inc. Business Overview
7.4.3 RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Major Product Offerings
7.4.4 RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.4.5 RegenxBio, Inc. Key News & Latest Developments
7.5 Takeda Pharmaceutical Company Limited
7.5.1 Takeda Pharmaceutical Company Limited Company Summary
7.5.2 Takeda Pharmaceutical Company Limited Business Overview
7.5.3 Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Major Product Offerings
7.5.4 Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.5.5 Takeda Pharmaceutical Company Limited Key News & Latest Developments
7.6 Orchard Therapeutics Plc
7.6.1 Orchard Therapeutics Plc Company Summary
7.6.2 Orchard Therapeutics Plc Business Overview
7.6.3 Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Major Product Offerings
7.6.4 Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.6.5 Orchard Therapeutics Plc Key News & Latest Developments
7.7 Magenta Therapeutics
7.7.1 Magenta Therapeutics Company Summary
7.7.2 Magenta Therapeutics Business Overview
7.7.3 Magenta Therapeutics Metachromatic Leukodystrophy Treatment Major Product Offerings
7.7.4 Magenta Therapeutics Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.7.5 Magenta Therapeutics Key News & Latest Developments
7.8 Shire Plc
7.8.1 Shire Plc Company Summary
7.8.2 Shire Plc Business Overview
7.8.3 Shire Plc Metachromatic Leukodystrophy Treatment Major Product Offerings
7.8.4 Shire Plc Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.8.5 Shire Plc Key News & Latest Developments
7.9 Oxyrane
7.9.1 Oxyrane Company Summary
7.9.2 Oxyrane Business Overview
7.9.3 Oxyrane Metachromatic Leukodystrophy Treatment Major Product Offerings
7.9.4 Oxyrane Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.9.5 Oxyrane Key News & Latest Developments
7.10 NanoMedSyn
7.10.1 NanoMedSyn Company Summary
7.10.2 NanoMedSyn Business Overview
7.10.3 NanoMedSyn Metachromatic Leukodystrophy Treatment Major Product Offerings
7.10.4 NanoMedSyn Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.10.5 NanoMedSyn Key News & Latest Developments
7.11 Juventas Therapeutics
7.11.1 Juventas Therapeutics Company Summary
7.11.2 Juventas Therapeutics Business Overview
7.11.3 Juventas Therapeutics Metachromatic Leukodystrophy Treatment Major Product Offerings
7.11.4 Juventas Therapeutics Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.11.5 Juventas Therapeutics Key News & Latest Developments
7.12 GenSight Biologics
7.12.1 GenSight Biologics Company Summary
7.12.2 GenSight Biologics Business Overview
7.12.3 GenSight Biologics Metachromatic Leukodystrophy Treatment Major Product Offerings
7.12.4 GenSight Biologics Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.12.5 GenSight Biologics Key News & Latest Developments
7.13 Inozyme Pharma
7.13.1 Inozyme Pharma Company Summary
7.13.2 Inozyme Pharma Business Overview
7.13.3 Inozyme Pharma Metachromatic Leukodystrophy Treatment Major Product Offerings
7.13.4 Inozyme Pharma Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.13.5 Inozyme Pharma Key News & Latest Developments
7.14 ONL Therapeutics
7.14.1 ONL Therapeutics Company Summary
7.14.2 ONL Therapeutics Business Overview
7.14.3 ONL Therapeutics Metachromatic Leukodystrophy Treatment Major Product Offerings
7.14.4 ONL Therapeutics Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.14.5 ONL Therapeutics Key News & Latest Developments
7.15 AngioChem
7.15.1 AngioChem Company Summary
7.15.2 AngioChem Business Overview
7.15.3 AngioChem Metachromatic Leukodystrophy Treatment Major Product Offerings
7.15.4 AngioChem Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.15.5 AngioChem Key News & Latest Developments
7.16 Cabaletta Bio
7.16.1 Cabaletta Bio Company Summary
7.16.2 Cabaletta Bio Business Overview
7.16.3 Cabaletta Bio Metachromatic Leukodystrophy Treatment Major Product Offerings
7.16.4 Cabaletta Bio Metachromatic Leukodystrophy Treatment Revenue in Global Market (2018-2023)
7.16.5 Cabaletta Bio Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
世界の異染性白質ジストロフィー治療薬市場予測2023-2029：錠剤、カプセル、その他 |
| 【英語タイトル】Metachromatic Leukodystrophy Treatment Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5765 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：108 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界の異染性白質ジストロフィー治療薬市場規模と予測を収録しています。・世界の異染性白質ジストロフィー治療薬市場：売上、2018年-2023年、2024年-2029年 ・世界の異染性白質ジストロフィー治療薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の異染性白質ジストロフィー治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「錠剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 異染性白質ジストロフィー治療薬のグローバル主要企業は、ArmaGen, Inc.、 GlaxoSmithKline Plc、 Recursion Pharmaceuticals, Inc.、 RegenxBio, Inc.、 Takeda Pharmaceutical Company Limited、 Orchard Therapeutics Plc、 Magenta Therapeutics、 Shire Plc、 Oxyrane、 NanoMedSyn、 Juventas Therapeutics、 GenSight Biologics、 Inozyme Pharma、 ONL Therapeutics、 AngioChem、 Cabaletta Bioなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、異染性白質ジストロフィー治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の異染性白質ジストロフィー治療薬市場：タイプ別、2018年-2023年、2024年-2029年 世界の異染性白質ジストロフィー治療薬市場：タイプ別市場シェア、2022年 ・錠剤、カプセル、その他 世界の異染性白質ジストロフィー治療薬市場：用途別、2018年-2023年、2024年-2029年 世界の異染性白質ジストロフィー治療薬市場：用途別市場シェア、2022年 ・病院、診療所、検査室、その他 世界の異染性白質ジストロフィー治療薬市場：地域・国別、2018年-2023年、2024年-2029年 世界の異染性白質ジストロフィー治療薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における異染性白質ジストロフィー治療薬のグローバル売上、2018年-2023年 ・主要企業における異染性白質ジストロフィー治療薬のグローバル売上シェア、2022年 ・主要企業における異染性白質ジストロフィー治療薬のグローバル販売量、2018年-2023年 ・主要企業における異染性白質ジストロフィー治療薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 ArmaGen, Inc.、 GlaxoSmithKline Plc、 Recursion Pharmaceuticals, Inc.、 RegenxBio, Inc.、 Takeda Pharmaceutical Company Limited、 Orchard Therapeutics Plc、 Magenta Therapeutics、 Shire Plc、 Oxyrane、 NanoMedSyn、 Juventas Therapeutics、 GenSight Biologics、 Inozyme Pharma、 ONL Therapeutics、 AngioChem、 Cabaletta Bio ************************************************************* ・調査・分析レポートの概要 異染性白質ジストロフィー治療薬市場の定義 市場セグメント 世界の異染性白質ジストロフィー治療薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の異染性白質ジストロフィー治療薬市場規模 世界の異染性白質ジストロフィー治療薬市場規模：2022年 VS 2029年 世界の異染性白質ジストロフィー治療薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの異染性白質ジストロフィー治療薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の異染性白質ジストロフィー治療薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：錠剤、カプセル、その他 異染性白質ジストロフィー治療薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、診療所、検査室、その他 異染性白質ジストロフィー治療薬の用途別グローバル売上・予測 ・地域別市場分析 地域別異染性白質ジストロフィー治療薬市場規模 2022年と2029年 地域別異染性白質ジストロフィー治療薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） ArmaGen, Inc.、 GlaxoSmithKline Plc、 Recursion Pharmaceuticals, Inc.、 RegenxBio, Inc.、 Takeda Pharmaceutical Company Limited、 Orchard Therapeutics Plc、 Magenta Therapeutics、 Shire Plc、 Oxyrane、 NanoMedSyn、 Juventas Therapeutics、 GenSight Biologics、 Inozyme Pharma、 ONL Therapeutics、 AngioChem、 Cabaletta Bio ... |
Metachromatic leukodystrophy disease (MLD) is a deadly genetic condition caused by mutations in the ARSA gene that results in brain impairment and developmental retardation. In its most severe and prevalent forms, young children rapidly lose their capacity to walk, communicate, and interact with their surroundings, and the majority die before reaching puberty.Metachromatic leukodystrophy is characterized by sulfatide deposition in cells. This accumulating has a particular impact on nervous system cells that create myelin, a material that insulates and protects neurons. White matter is a tissue made composed of nerve cells coated with myelin. This damages the protective myelin sheathing the neurons, leading to gradual deterioration of the brain and nervous system functioning.This disease has three forms that are Late Infantile Form, Juvenile Form, and Adult Form. Pipeline products, which can only treat symptoms of the disease, are among the medical treatment. These products have the potential to prevent nerve damage, reduce the development of the illness, avoid complications, and provide pain relief.
This report aims to provide a comprehensive presentation of the global market for Metachromatic Leukodystrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metachromatic Leukodystrophy Treatment. This report contains market size and forecasts of Metachromatic Leukodystrophy Treatment in global, including the following market information:
Global Metachromatic Leukodystrophy Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Metachromatic Leukodystrophy Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Tablet Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Metachromatic Leukodystrophy Treatment include ArmaGen, Inc., GlaxoSmithKline Plc, Recursion Pharmaceuticals, Inc., RegenxBio, Inc., Takeda Pharmaceutical Company Limited, Orchard Therapeutics Plc, Magenta Therapeutics, Shire Plc and Oxyrane, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Metachromatic Leukodystrophy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metachromatic Leukodystrophy Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Metachromatic Leukodystrophy Treatment Market Segment Percentages, by Type, 2022 (%)
Tablet
Capsule
Others
Global Metachromatic Leukodystrophy Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Metachromatic Leukodystrophy Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Laboratory
Others
Global Metachromatic Leukodystrophy Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Metachromatic Leukodystrophy Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metachromatic Leukodystrophy Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Metachromatic Leukodystrophy Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
ArmaGen, Inc.
GlaxoSmithKline Plc
Recursion Pharmaceuticals, Inc.
RegenxBio, Inc.
Takeda Pharmaceutical Company Limited
Orchard Therapeutics Plc
Magenta Therapeutics
Shire Plc
Oxyrane
NanoMedSyn
Juventas Therapeutics
GenSight Biologics
Inozyme Pharma
ONL Therapeutics
AngioChem
Cabaletta Bio
Outline of Major Chapters:
Chapter 1: Introduces the definition of Metachromatic Leukodystrophy Treatment, market overview.
Chapter 2: Global Metachromatic Leukodystrophy Treatment market size in revenue.
Chapter 3: Detailed analysis of Metachromatic Leukodystrophy Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Metachromatic Leukodystrophy Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界の異染性白質ジストロフィー治療薬市場予測2023-2029：錠剤、カプセル、その他] (コード：MMG23JU5765)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の異染性白質ジストロフィー治療薬市場予測2023-2029：錠剤、カプセル、その他]についてメールでお問い合わせ |
